We present the first aggregate estimates of OS and PFS for RM-NPC patients receiving first and second-line or higher treatment settings, which could inform the design of future clinical trials in this disease setting.
No takes yet. Share an insight, caveat, or question.
Prawira et al. (2017) studied this question.